ClinicalTrials.gg
Not yet recruitingNCT07668466CBT005Updated Jun 25, 2026

Intradiscal rhGDF-6 for the Treatment of Lumbar Disc Degeneration

A Phase 1/2 interventional study of High Dose and Low Dose in Disc Degenerative Disease and Back Pain, sponsored by Cartago Biotech Pty Ltd. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Cartago Biotech Pty Ltd · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Intervertebral Disc Degeneration with a site in Australia — 4 open to participants now, 5 under way, none of them phase 3. Intervertebral Disc Degeneration · Australia.

Planned enrollment
6th of 12
60 · median 60
Started
2026
with 1 other
Phase 1/2
3 of 13
2 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
Cartago Biotech Pty Ltd

Among the 13 studies in Intervertebral Disc Degeneration with a site in Australia, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 1/2, and was the 13th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

4 of the 13 studies in Intervertebral Disc Degeneration with a site in Australia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Intervertebral Disc Degeneration with a site in Australia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to find out if a new medicine can help people who have long-lasting back pain caused by damaged spinal discs. The study will also check if the medicine is safe to use.

The main questions this study aims to answer are:

Is the medicine safe, and what amount works best? Can it reduce long-term back pain?

Researchers will test a medicine called CBT005, which contains a healing protein, by injecting it into the spinal discs. They will watch closely to see how people respond to the treatment.

Participants will:

Receive one study injection into the spinal disc Visit the clinic in person during the first 12 months for checkups Receive phone calls at 24 and 36 months to see how they are doing Still be able to get other pain treatments in the future, including surgery, if needed

03

Conditions studied

  • Disc Degenerative Disease
  • Back Pain

Keywords

  • Back Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Persistent low back pain, with at least 3 months of non-surgical therapy, at one symptomatic disc or two symptomatic lumbar disc levels (from L2 to S1).
  2. MRI scans show Pfirrmann disc degeneration grade 2 to 4 or High Intensity Zone (HIZ) signal change with or without Modic endplate changes.
  3. Symptoms are a fair bit or a lot bothersome, which require medication or other types of treatments or very disrupting (in response to question*).
  4. Preoperative Oswestry Disability Index (ODI) score greater than or equal to 30%
  5. Visual Analog Score for back pain ≥40 mm.
  6. Any gender, 18 years of age or older
  7. Clinician diagnosed discogenic pain
  8. A signed HREC-approved Form
  9. Able to meet the protocol follow-up schedule and activities
  10. Females of must have a negative urine/serum pregnancy test at screening (Baseline Visit) and on the day of administration prior to injection *Question defined in full protocol

Exclusion criteria

Exclusion Criteria

  1. People unable to have an MRI
  2. Abnormal neurological exam at baseline (e.g., chronic radiculopathy)
  3. Active radicular pain due to anatomical compression such as stenosis or disc herniation
  4. Symptomatic facet joints and/or severe facet degeneration at the index level or adjacent segments
  5. Symptomatic Sacro-iliac joint
  6. MRI findings demonstrate any of the following: Suspected disc appears normal or >50% decrease in disc height or Presence of symptomatic osteophytes
  7. Any prior lumbar spinal surgeries at suspected symptomatic level; prior surgery at the adjacent levels is acceptable including fusion or arthroplasty, provided the said adjacent level is not independently symptomatic.
  8. Presence of spondylolisthesis (anterolisthesis, retrolisthesis is acceptable)
  9. Symptomatic disc degeneration at more than 2 lumbar levels (multi-level disc degeneration based on MRI findings is acceptable with up to two symptomatic level. Only the symptomatic levels will be treated)
  10. Evidence of active infection
  11. therapy within 3 months prior to product administration
  12. Either continuous or cumulative use of more than 2 months use in the past 6 months of an oral or systemic . Inhaled steroids are acceptable
  13. Tumor in the spine
  14. People with any current and previous cancer. An exemption to this is previous BCCs which have been successfully removed.
  15. Non-contained herniated nucleus pulposus
  16. Any prior intradiscal therapies (chemonucleolysis, IDET, intradiscal steroid injection) at the same level being treated, other than rhGDF-6.
  17. Any non-intradiscal steroid injection less than 2 months prior to administration. Does not include isolated joint injections outside the lumbar region.
  18. Nerve block injection less than 2 months prior to injection of study medication.
  19. Known disease
  20. Type 1 Insulin-dependent diabetes mellitus (Type II, non-insulin dependent diabetes mellitus is allowed)
  21. Pregnant or lactating, or wishes to become pregnant within the first 12 months of the study
  22. Involved in pending litigation of the spine (including workers compensation cases)
  23. Demonstrates signs of non-organic pain (e.g., Waddell's Signs)
  24. Based on clinical history, physical examination and participant presentation, participant has, or is suspected to have, a history of alcohol and/or drug abuse that would preclude participants from providing adequate consent and/or complying with study requirements
  25. Prisoner
  26. Morbid Obesity, defined as (BMI) ≥40
  27. less than 2 years
  28. Any significant psychological disturbance past or present, that could impair the consent process or ability to complete participant self-report questionnaires
  29. Any reason not cited above that, in the opinion of the Principal Investigator, would pose a risk to either the participant or to the integrity of the clinical trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Low dose

    2mg dose of Growth differentiation factor 6

    Biological: Low Dose

  • Active comparator
    High dose

    4mg dose of Growth differentiation factor 6

    Biological: High Dose

Interventions

  • BiologicalHigh Dose

    High Dose: 4 mg dose of Growth differentiation factor 6

  • BiologicalLow Dose

    Low dose: 2mg dose of Growth differentiation factor 6

06

What researchers measure

Primary outcomes

  1. Neurological Status

    Safety will be evaluated by assessing neurologic status and the type, frequency, and severity of adverse events through 12 months.

    Time frame: From enrollment through to 12 months

  2. Oswestry Disability Index (ODI)

    The Oswestry Disability Index (ODI) assesses functional limitations in activities of daily living related to back pain. The ODI consists of 10 questions, each addressing a specific aspect of daily living affected by back pain, such as pain intensity, personal care, lifting, walking, sitting, standing, sleeping, sexual activity, social life, and travel. Each question has six statements that correlate to a score of 0 to 5. The patient chooses the statement that best describes their current condition, with higher scores indicating greater disability. The total score is calculated by summing the individual question scores and then dividing by the total possible score (which is 50) and multiplying by 100 to get a percentage disability.

    Time frame: Enrollment through to 12 months

Secondary outcomes

  1. Visual Analog Scale

    VAS will be meausred on a millimeter (mm) scale. It is a 100-mm continuous line used to measure subjective experiences like pain, fatigue, or quality of life. Scores will be calculated by measuring the distance in millimeters from the left anchor (usually "no symptom") to the patient's mark.

    Time frame: From enrollment through to 12 months

  2. EQ5D-5L

    The EQ-5D-5L is a widely used generic health-related quality of life instrument developed in the 1980s by the EuroQol Group to assess and compare health status across different diseases and populations. An EQ-5D 5L health state is converted into a utility score by subtracting the weighted values assigned to the selected levels in each of the five health dimensions from a baseline of 1. The weights assigned to each level within the health dimensions reflect the relative impact of those health problems on overall quality of life.

    Time frame: From enrollment through to 12 months

07

Study locations

1 site
  • Spine & Scoliosis Service
    Kogarah, New South Wales 2217, Australia
08

References and documents

Publications

  • Wei A, Williams LA, Bhargav D, Shen B, Kishen T, Duffy N, Diwan AD. BMP13 prevents the effects of annular injury in an ovine model. Int J Biol Sci. 2009 Jun 3;5(5):388-96. doi: 10.7150/ijbs.5.388. PubMed 19521550 ↗
  • Miyazaki S, Diwan AD, Kato K, Cheng K, Bae WC, Sun Y, Yamada J, Muehleman C, Lenz ME, Inoue N, Sah RL, Kawakami M, Masuda K. ISSLS PRIZE IN BASIC SCIENCE 2018: Growth differentiation factor-6 attenuated pro-inflammatory molecular changes in the rabbit anular-puncture model and degenerated disc-induced pain generation in the rat xenograft radiculopathy model. Eur Spine J. 2018 Apr;27(4):739-751. doi: 10.1007/s00586-018-5488-1. Epub 2018 Feb 19. PubMed 29460012 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Aug 2028, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 25, 2026
StartEst.
Jul 4, 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Dec 1, 2030
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07668466
Lead sponsor
Cartago Biotech Pty Ltd
Responsible party
Sponsor
First posted
Jun 25, 2026
Start date
Jul 4, 2026 (estimated)
Primary completion
Aug 31, 2028 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Jun 25, 2026

Study contacts

Ashish Diwan
Contact
ashish@cartago-biotech.com
+61 409257177
Neha Chopra
Contact
neha@cartago-biotech.com
+61 478943074

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion